The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Site Management Organizations (SMO) Market by Therapeutic Areas (Oncology, CNS, Cardiovascular, Infectious Diseases and Others), Trial Phases (Phase I, Phase II, Phase III and Phase IV), Clinical Trial Components (Site Management, Onsite Monitoring, Project Management and Others), Type of Interventions (Therapeutics, Devices and Surgical Procedure) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2021-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    October 2021

  • Pages
    270

  • View Count
    398

Example Insights

Site-Management-Organizations-Market-Context Site-Management-Organizations-Market-List Site-Management-Organizations-Market-Distribution Site-Management-Organizations-Market-Company-Competitiveness-Analysis
Site-Management-Organizations-Market-Partnerships-and-Collaborations Site-Management-Organizations-Market-Funding-and-Investments Site-Management-Organizations-Market-Clinical-Trial-Key-Insights Site-Management-Organizations-Market-Global-Demand-for-Study-Participants
Site-Management-Organizations-Market-Distribution-by-Type-of-Intervention Site-Management-Organizations-Market-Distribution-by-Geographical-Region    

Overview

Clinical trials form an integral part of the overall drug development process, enabling the necessary evaluation of the safety and efficacy of a drug candidate. Studies suggest that around 40% of the total investment made for the development of drug candidate is dedicated to clinical trials; this is equivalent to an expenditure of USD 78 billion annually. However, the conduct of such trials is often fraught with challenges, including scientific and operational complexity, concerns associated with recruitment and retention of suitable patients, issues related to data handling and increasingly stringent regulatory guidelines. Further, owing to the inherent complexity of the overall process and involvement of several different stakeholders, these trials are prone to delays. In fact, over 80% of the clinical trials are delayed by at least one to six months, while only 10% of the studies are completed on time. Therefore, innovators in the pharmaceutical industry are constantly developing ways to improve the process of conducting clinical trials and managing research sites. Amidst other alternatives, outsourcing various trial operations to a specialized service provider, such as site management organizations (SMOs), has emerged as a viable option for various developers. The advantages of engaging such specialized service providers are numerous and enable sponsors to meet their clinical research timelines. In addition, SMOs can facilitate rapid patient recruitment, reduce study timelines, and manage the entire clinical trial processes and administrative work for their clients. Moreover, drug / medical device developers, and even the contract research organizations (CROs), can employ the therapeutic and operational expertise, global site networks and well-established processes and tools offered by SMOs in order to carry out their clinical research and site management activities in a cost and time efficient manner.

Currently, around 250 companies claim to be actively providing clinical site management services to drug and medical device developers across the world. Recently, there has been a lot of activity within the site management market, primarily focused on consolidation of affiliated capabilities, service portfolio expansions and collaborations to extend geographical reach. The aforementioned developments may be attributed to the growing preference for one-stop-shops among sponsor companies, and the gradual acceptance of outsourcing as a viable and beneficial operating model for conducting clinical trials and managing research sites. With the growing complexity, as well as rise in the number of clinical trials being registered, the demand for SMOs is anticipated to grow at a steady pace in the coming years.

Scope of the Report

The ‘Site Management Organizations Market – Distribution by Therapeutic Areas (Oncological Disorders, CNS Disorders, Infectious Diseases, Cardiovascular Diseases and Others), Trial Phases (Phase I, Phase II, Phase III and Phase IV), Clinical Trial Components (Site Management, Onsite Monitoring, Project Management and Others), Type of Interventions (Therapeutics, Devices and Surgical Procedure) and Key Geographies (North America, Europe, Asia-Pacific, Latin America, MENA, and RoW): Industry Trends and Global Forecasts, 2021-2035’ report features an extensive study of the current market landscape and future potential of the site management organizations market. The study features an in-depth analysis, highlighting the capabilities of clinical trial site management service providers engaged in this domain. Amongst other elements, the report features:

  • A detailed review of the overall landscape of companies offering clinical trial site management services to various organizations, including CROs, and pharmaceutical, biotechnology and medical devices companies, along with information on their year of establishment, company size (in terms of employee count), location of headquarters and geographical reach of the companies. The chapter also covers details related to type of service(s) offered (site identification and selection, study feasibility, study protocol development, patient recruitment, patient retention, project management, regulatory support, clinical monitoring, site management, clinical trial data management, patient follow-up, real-time enquiry / information support, study contract, budget and expense management / contract negotiation, hiring / training study investigator, logistics management, quality control and quality assurance and others) and therapeutic expertise of service providers.
  • An insightful 2×2 representation of the competitiveness analysis of various service providers segregated into three peer groups based on location of their headquarters (North America, Europe, and Asia-Pacific and RoW). The companies were further distributed across the geographies, based on their employee count, into three categories, namely small (1-200 employees), mid-sized (201-500 employees) and large (>500 employees), highlighting the top players in this domain, based on their respective capabilities.
  • An analysis of the partnerships that have been inked by stakeholders engaged in this domain, during the period 2016-2021 (till August). The various types of partnerships captured in our study include (in alphabetical order) acquisitions, clinical trial agreements, clinical trial site agreements, joint ventures, mergers, product / technology integration agreements, research agreements, service alliances, technology licensing agreements, technology utilization agreements and other related agreements. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, focus area and most active players (in terms of number of partnerships). It also highlights the regional distribution of the collaborations.
  • A detailed analysis of various investments received by players engaged in this domain during the period 2015-2021 (till August), based on several relevant parameters, such as year of investment, number of funding instances, amount invested, type of funding (grant, seed, venture capital, secondary offering, other equity, debt and others) and type of investor, along with information on the most active players (in terms of number of funding instances and amount raised), most active investors (in terms  of number of funding instances) and geographical distribution (in terms of number of funding instances and amount invested).
  • An in-depth analysis of completed, ongoing and planned clinical studies during the period 2016-2021 (till August), to present clinical trial key insights, based on several relevant parameters, such as trial registration year, number of enrolled patients, trial status, trial phase, type of sponsor and geographical distribution of number of trials and enrolled patient population.
  • An informed estimate of the annual demand for clinical study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.
  • Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) that offer various clinical trial site management services, across North America, Europe and Asia-Pacific. Each profile provides an overview of the company, featuring information on the year of establishment, number of employees, location of their headquarters, details related to its site management service portfolio, recent developments, and an informed future outlook.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of the site management organizations market over the coming decades. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] therapeutic areas (oncological disorders, CNS disorders, infectious diseases, respiratory disorders, cardiovascular diseases, endocrine disorders, gastrointestinal disorders, musculoskeletal diseases, immunological disorders and others), [B] clinical trial phases (phase I, phase II, phase III and phase IV), [C] clinical trial components (site management, onsite monitoring, project management, data management, regulatory affairs, logistics, quality control and others), [D] types of interventions (therapeutics, devices and surgical procedure) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and RoW).  To account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Vinod Gyanchandani (Country Head - Clinical Operations, GDD Experts)
  • Marisa Vico (Medical Director and Operations Manager, SMO – Dra. Marisa Vico)
  • Eugene Winifred (Project Manager, Syncretic Clinical Research Services)

Key Questions Answered

  • Who are the leading players in the clinical trial site management domain?
  • What is the relative competitiveness of different site management organizations?
  • What type of partnership models are commonly adopted by stakeholders in this industry?
  • What is the capital investments trend in site management organizations domain?
  • Which are the most active clinical trial centers?
  • What are the major market trends and driving factors that are likely to impact the growth of site management organizations market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the site management organizations market in the short to mid-term, and long term.

Chapter 3 provides a general introduction to SMOs, featuring information on their working model and major differences between a SMO and CRO. Further, it provides details related to the various services offered by SMOs. Additionally, it highlights the advantages offered by SMOs acting as one-stop-shops. The chapter concludes with a discussion on the anticipated opportunity areas for SMOs and inputs on their projected growth in the coming years.

Chapter 4 features a detailed review of the current market landscape of around 250 companies offering clinical trial site management services. Additionally, it features an in-depth analysis of service providers, based on a number of relevant parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. The chapter also covers details about type of site management service(s) offered (site identification and selection, study feasibility, study protocol development, patient recruitment, patient retention, project management, regulatory support, clinical monitoring, site management, clinical trial data management, patient follow-up, real-time enquiry / information support, study contract, budget and expense management / contract negotiation, hiring / training study investigator, logistics management, quality control and quality assurance and others), therapeutic expertise of service providers (oncological disorders, CNS disorders, infectious diseases, respiratory disorders, cardiovascular diseases, endocrine disorders, gastrointestinal disorders, musculoskeletal diseases, immunological disorders, dermatological disorders and others) and geographical reach of the companies.

Chapter 5 presents an insightful competitiveness analysis of the site management organizations, located in North America, Europe and Asia-Pacific. The companies are further segmented based on their employee count, into three categories, namely small (1-200 employees), mid-sized (201-500 employees) and large (>500 employees) across these geographies. The analysis compares the service providers on the basis of various parameters, such as site management services offered, therapeutic expertise, geographical reach and year of establishment. In the chapter, stakeholder entities have been plotted on a 2×2 matrices, having a company’s experience (based on its year of establishment) (abscissa) and company competitiveness (ordinate) as the two axes. 

Chapter 6 provides detailed profiles of the prominent players (shortlisted based on a proprietary criterion) that are active in offering clinical trial site management services in North America. Each profile provides an overview of the company, information related to its site management service portfolio, and details on recent developments, as well as an informed future outlook.

Chapter 7 provides detailed profiles of the prominent players (shortlisted based on a proprietary criterion) that are active in offering clinical trial site management services in Europe. Each profile provides an overview of the company, information related to its site management service portfolio, and details on recent developments, as well as an informed future outlook.

Chapter 8 provides detailed profiles of the prominent players (shortlisted based on a proprietary criterion) that are active in offering clinical trial site management services in Asia-Pacific. Each profile provides an overview of the company, information related to its site management service portfolio, and details on recent developments, as well as an informed future outlook.

Chapter 9 features an analysis of the various collaborations and partnerships that have been inked by stakeholders engaged in this domain, during the period 2016-2021 (till August). It includes a brief description of the partnership models (including service alliances, clinical trial agreements, acquisitions, product / technology integration agreements, technology utilization agreements, R&D agreements, mergers, joint ventures, clinical trial site agreements, technology licensing agreements and others) adopted by stakeholders in this domain. Further, it comprises of analysis based on year of agreement, type of agreement, focus area and most active player(s) (in terms of number of partnerships inked). Further, the chapter includes a world map representation of all the deals inked in this field in the period 2016-2021, highlighting both intercontinental and intracontinental partnership activity.

Chapter 10 presents details on various investments received by various players engaged in clinical trial site management domain. It also includes an analysis of the funding instances that have taken place in the market, during the period 2015-2021 (till August), highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 11 provides a detailed analysis of completed, ongoing, and planned clinical studies during the period 2016-2021 (till August), to present clinical trial key insights, highlighting prevalent trends across various relevant parameters, such as trial registration year, number of enrolled patients, trial status, trial phase, type of sponsor and geographical distribution of number of trials and enrolled patient population.

Chapter 12 provides an informed estimate of the annual demand for clinical study participants, taking into account the target patient population in ongoing and planned clinical trials, sponsored by both industry and non-industry players.

Chapter 13 presents an insightful market forecast analysis, highlighting the likely growth of the site management organizations market till the year 2035. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] therapeutic areas (oncological disorders, CNS disorders, infectious diseases, respiratory disorders, cardiovascular diseases, endocrine disorders, gastrointestinal disorders, musculoskeletal diseases, immunological disorders and others), [B] clinical trial phases (phase I, phase II, phase III and phase IV), [C] clinical trial components (site management, onsite monitoring, project management, data management, regulatory affairs, logistics, quality control and others), [D] types of interventions (therapeutics, devices and surgical procedure) and [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and RoW)

Chapter 14 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 15 provides the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the site management domain. In this chapter, we have presented the details of our conversation with Vinod Gyanchandani (Country Head - Clinical Operations, GDD Experts), Marisa Vico (Medical Director and Operations Manager, SMO – Dra. Marisa Vico) and Eugene Winifred (Project Manager, Syncretic Clinical Research Services).

Chapter 16 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Site Management Organizations
3.3. Role of Site Management Organizations in Clinical Trials
3.4. Services Offered by Site Management Organizations
3.5. Advantages of One-Stop-Shops
3.6. Concluding Remarks

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Site Management Organizations: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Service(s) Offered
4.2.5. Analysis by Therapeutic Expertise
4.2.6. Analysis by Geographical Reach

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Site Management Organizations: Company Competitiveness Analysis
5.4.1. Competitiveness Analysis: Site Management Organizations in North America
5.4.1.1. Competitiveness Analysis: Small Companies in North America
5.4.1.2. Competitiveness Analysis: Mid-sized Companies in North America
5.4.1.3. Competitiveness Analysis: Large Companies in North America

5.4.2. Competitiveness Analysis: Site Management Organizations in Europe
5.4.2.1. Competitiveness Analysis: Small Companies in Europe
5.4.2.2. Competitiveness Analysis: Mid-sized Companies in Europe
5.4.2.3. Competitiveness Analysis: Large Companies in Europe

5.4.3. Competitiveness Analysis: Site Management Organizations in Asia-Pacific and Rest of the World
5.4.3.1. Competitiveness Analysis: Small Companies in Asia-Pacific and Rest of the World
5.4.3.2. Competitiveness Analysis: Mid-sized Companies in Asia-Pacific and Rest of the World
5.4.3.3. Competitiveness Analysis: Large Companies in Asia-Pacific and Rest of the World

6. COMPANY PROFILES: SITE MANAGEMENT ORGANIZATIONS IN NORTH AMERICA
6.1. Chapter Overview
6.2. FOMAT Medical Research
6.2.1. Company Overview
6.2.2. Clinical Trial Site Management Services
6.2.3. Recent Developments and Future Outlook

6.3. Parexel
6.3.1. Company Overview
6.3.2. Clinical Trial Site Management Services
6.3.3. Recent Developments and Future Outlook

6.4. Pharm-Olam
6.4.1. Company Overview
6.4.2. Clinical Trial Site Management Services
6.4.3. Recent Developments and Future Outlook
6.5. Veristat
6.5.1. Company Overview
6.5.2. Clinical Trial Site Management Services
6.5.3. Recent Developments and Future Outlook

6.6. WCCT Global
6.6.1. Company Overview
6.6.2. Clinical Trial Site Management Services
6.6.3. Recent Developments and Future Outlook

6.7. Worldwide Clinical Trials
6.7.1. Company Overview
6.7.2. Clinical Trial Site Management Services
6.7.3. Recent Developments and Future Outlook

7. COMPANY PROFILES: SITE MANAGEMENT ORGANIZATIONS IN EUROPE
7.1. Chapter Overview
7.2. CROMSOURCE
7.2.1. Company Overview
7.2.2. Clinical Trial Site Management Services
7.2.3. Recent Developments and Future Outlook

7.3. Fidelis Research
7.3.1. Company Overview
7.3.2. Clinical Trial Site Management Services
7.3.3. Recent Developments and Future Outlook

7.4. Scandinavian CRO
7.4.1. Company Overview
7.4.2. Clinical Trial Site Management Services
7.4.3. Recent Developments and Future Outlook
7.5. TFS HealthScience
7.5.1. Company Overview
7.5.2. Clinical Trial Site Management Services
7.5.3. Recent Developments and Future Outlook

7.6. Trialbee
7.6.1. Company Overview
7.6.2. Clinical Trial Site Management Services
7.6.3. Recent Developments and Future Outlook

8. COMPANY PROFILES: SITE MANAGEMENT ORGANIZATIONS IN ASIA-PACIFIC
8.1. Chapter Overview
8.2. CMIC Group
8.2.1. Company Overview
8.2.2. Clinical Trial Site Management Services
8.2.3. Recent Developments and Future Outlook

8.3. George Clinical
8.3.1. Company Overview
8.3.2. Clinical Trial Site Management Service
8.3.3. Recent Developments and Future Outlook

8.4. Tigermed
8.4.1. Company Overview
8.4.2. Clinical Trial Site Management Services
8.4.3. Recent Developments and Future Outlook

8.5. Veeda Clinical Research
8.5.1. Company Overview
8.5.2. Clinical Trial Site Management Services
8.5.3. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Site Management Organizations: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Focus Area
9.3.5. Most Active Players: Analysis by Number of Partnerships
9.3.6. Geographical Analysis
9.3.6.1. Region-wise Distribution
9.3.6.2. Country-wise Distribution

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Site Management Organizations: Funding and Investment Analysis
10.3.1. Analysis by Year of Investment
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Year-wise Analysis by Type of Funding and Amount Invested
10.3.5. Most Active Players: Analysis by Number of Funding Instances
10.3.6. Most Active Investors: Analysis by Number of Funding Instances
10.3.7. Analysis by Type of Investor
10.3.8. Analysis by Geography

11. KEY INSIGHTS FROM CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Site Management Organizations: Clinical Trial Key Insights
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
11.3.3. Analysis by Trial Status
11.3.4. Analysis by Trial Registration Year and Trial Status
11.3.5. Analysis by Trial Phase
11.3.6. Analysis by Trial Phase and Enrolled Patient Population
11.3.7. Analysis by Trial Registration Year and Trial Phase (in term of Number of Clinical Trials)
11.3.8. Analysis by Trial Registration Year and Trial Phase (in terms of Number of Enrolled Patient Population)
11.3.9. Analysis by Type of Sponsor / Collaborator
11.3.10. Geographical Analysis by Number of Clinical Trials
11.3.11. Geographical Analysis by Enrolled Patient Population

12. ANALYSIS OF DEMAND FOR CLINICAL TRIAL PARTICIPANTS
12.1. Chapter Overview
12.2. Methodology and Key Assumptions
12.3. Global Demand for Clinical Trial Participants: Analysis by Enrolled Patient Population
12.3.1. Analysis of Demand by Trial Phase
12.3.2. Analysis of Demand by Therapeutic Area
12.3.3. Geographical Demand by Enrolled Patient Population

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Site Management Organizations Market, 2021-2035
13.4. Site Management Organizations Market, 2021 and 2035: Distribution by Therapeutic Area
13.5. Site Management Organizations Market, 2021-2035: Distribution by Trial Phase
13.6. Site Management Organizations Market, 2021-2035: Distribution by Clinical Trial Components
13.7. Site Management Organizations Market, 2021-2035: Distribution by Type of Intervention
13.8. Site Management Organizations Market, 2021 and 2035: Distribution by Region
13.8.1. Site Management Organizations Market, 2021 and 2035: Distribution by Country
13.8.2. Site Management Organizations Market in North America, 2021-2035
13.8.2.1. Site Management Organizations Market in the US, 2021-2035
13.8.2.2. Site Management Organizations Market in Canada, 2021-2035
13.8.2.3. Site Management Organizations Market in Rest of North America, 2021-2035

13.8.3. Site Management Organizations Market in Europe, 2021-2035
13.8.3.1. Site Management Organizations Market in the UK, 2021-2035
13.8.3.2. Site Management Organizations Market in France, 2021-2035
13.8.3.3. Site Management Organizations Market in Germany, 2021-2035
13.8.3.4. Site Management Organizations Market in Spain, 2021-2035
13.8.3.5. Site Management Organizations Market in Italy, 2021-2035
13.8.3.6. Site Management Organizations Market in Rest of Europe, 2021-2035

13.8.4. Site Management Organizations Market in Asia-Pacific, 2021-2035
13.8.4.1. Site Management Organizations Market in China, 2021-2035
13.8.4.2. Site Management Organizations Market in Korea, 2021-2035
13.8.4.3. Site Management Organizations Market in India, 2021-2035
13.8.4.4. Site Management Organizations Market in Australia, 2021-2035
13.8.4.5. Site Management Organizations Market in Japan, 2021-2035
13.8.4.6. Site Management Organizations Market in Israel, 2021-2035
13.8.4.7. Site Management Organizations Market in Rest of Asia-Pacific, 2021-2035

13.8.5. Site Management Organizations Market in Latin America, 2021-2035
13.8.6. Site Management Organizations Market in MENA, 2021-2035
13.8.7. Site Management Organizations Market in Rest of the World, 2021-2035

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. GDD Experts
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Vinod Gyanchandani, Country Head-Clinical Operations

15.3. SMO – Dra. Marisa Vico
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Marisa Vico, Medical Director and Operations Manager

15.4. Syncretic Clinical Research Services
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Eugene Winifred, Project Manager

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Forecast
Figure 2.2 Executive Summary: Overall Market Landscape
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Clinical Trial Key Insights
Figure 2.6 Executive Summary: Analysis of Demand for Clinical Trial Participants
Figure 3.1 Working Model of Site Management Organizations
Figure 3.2 Services Offered by Site Management Organizations
Figure 4.1 Site Management Organizations: Distribution by Year of Establishment
Figure 4.2 Site Management Organizations: Distribution by Company Size
Figure 4.3 Site Management Organizations: Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Site Management Organizations: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Site Management Organizations: Distribution by Company Size and Location of Headquarters
Figure 4.6 Site Management Organizations: Distribution by Service(s) Offered
Figure 4.7 Site Management Organizations: Distribution by Location of Headquarters and Service(s) Offered
Figure 4.8 Site Management Organizations: Distribution by Therapeutic Expertise
Figure 4.9 Site Management Organizations: Distribution by Geographical Reach
Figure 5.1 Company Competitiveness Analysis: Small Players in North America
Figure 5.2 Company Competitiveness Analysis: Mid-sized Players in North America
Figure 5.3 Company Competitiveness Analysis: Large Players in North America
Figure 5.4 Company Competitiveness Analysis: Small Players in Europe
Figure 5.5 Company Competitiveness Analysis: Mid-sized Players in Europe
Figure 5.6 Company Competitiveness Analysis: Large Players in Europe
Figure 5.7 Company Competitiveness Analysis: Small Players in Asia-Pacific and Rest of the World
Figure 5.8 Company Competitiveness Analysis: Mid-sized Players in Asia-Pacific and Rest of the World
Figure 5.9 Company Competitiveness Analysis: Large Players in Asia-Pacific and Rest of the World
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2021
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partnership, 2016-2018 and 2019-2021
Figure 9.5 Partnerships and Collaborations: Distribution by Focus Area
Figure 9.6 Most Active Players: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Distribution by Region
Figure 9.8 Partnerships and Collaborations: Distribution by Country
Figure 10.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2015-2021
Figure 10.2 Funding and Investment Analysis: Cumulative Year-wise Trend by Amount Invested, 2015-2021 (USD Million)
Figure 10.3 Funding and Investment Analysis: Distribution by Type of Funding
Figure 10.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 10.5 Funding and Investment Analysis: Year-wise Distribution by Amount Invested and Type of Funding, 2015-2021 (USD Million)
Figure 10.6 Most Active Players: Distribution by Number of Funding Instances
Figure 10.7 Most Active Investors: Distribution by Number of Funding Instances
Figure 10.8 Funding and Investment Analysis: Distribution by Type of Investor
Figure 10.9 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 10.10 Funding and Investment Analysis: Distribution by Region (Continent-wise)
Figure 10.11 Funding and Investment Analysis: Distribution by Region (Country-wise)
Figure 10.12 Funding and Investment Analysis: Distribution of Amount Invested by Region (Country-wise) (USD Million)
Figure 11.1 Clinical Trial Key Insights: Scope and Methodology
Figure 11.2 Clinical Trial Key Insights: Cumulative Distribution by Trial Registration Year, 2016-2021
Figure 11.3 Clinical Trial Key Insights: Distribution by Trial Registration Year and Enrolled Patient Population, 2016-2021
Figure 11.4 Clinical Trial Key Insights: Distribution by Trial Status
Figure 11.5 Clinical Trial Key Insights: Distribution by Trial Registration Year and Trial Status, 2016-2021
Figure 11.6 Clinical Trial Key Insights: Distribution of Number of Trials by Trial Phase
Figure 11.7 Clinical Trial Key Insights: Distribution of Enrolled Patient Population by Trial Phase
Figure 11.8 Clinical Trial Key Insights: Year-wise Distribution by Number of Trials and Trial Phase, 2016-2021
Figure 11.9 Clinical Trial Key Insights: Year-wise Distribution by Number of Enrolled Patient Population and Trial Phase, 2016-2021
Figure 11.10 Clinical Trial Key Insights: Distribution by Type of Sponsor / Collaborator
Figure 11.11 Clinical Trial Key Insights: Geographical Distribution by Number of Clinical Trials
Figure 11.12 Clinical Trial Key Insights: Geographical Distribution by Enrolled Patient Population
Figure 12.1 Analysis of Demand for Clinical Trial Participants: Scope and Methodology
Figure 12.2 Global Demand for Clinical Trial Participants, 2021-2035 (Million Patients)
Figure 12.3 Global Demand for Clinical Trial Participants, 2021-2035: Distribution by Therapeutic Area (Million Patients)
Figure 12.4 Global Demand for Clinical Trial Participants, 2021-2035: Distribution by Trial Phase (Million Patients)
Figure 12.5 Global Demand for Clinical Trial Participants, 2021: Distribution by Region (Million Patients)
Figure 13.1 Global Site Management Organizations Market, 2021-2035 (USD Billion)
Figure 13.2 Site Management Organizations Market, 2021 and 2035: Distribution by Therapeutic Area (USD Billion)
Figure 13.3 Site Management Organizations Market, 2021-2035: Distribution by Trial Phase (USD Billion)
Figure 13.4 Site Management Organizations Market, 2021: Distribution by Clinical Trial Components (USD Billion)
Figure 13.5 Site Management Organizations Market, 2021-2035: Distribution by Type of Intervention (USD Billion)
Figure 13.6 Site Management Organizations Market, 2021 and 2035: Distribution by Region (USD Billion)
Figure 13.7 Site Management Organizations Market, 2021 and 2035: Distribution by Country (USD Billion)
Figure 13.8 Site Management Organizations Market in North America, 2021-2035 (USD Billion)
Figure 13.9 Site Management Organizations Market in the US, 2021-2035 (USD Billion)
Figure 13.10 Site Management Organizations Market in Canada, 2021-2035 (USD Billion)
Figure 13.11 Site Management Organizations Market in Rest of North America, 2021-2035 (USD Billion)
Figure 13.12 Site Management Organizations Market in Europe, 2021-2035 (USD Billion)
Figure 13.13 Site Management Organizations Market in the UK, 2021-2035 (USD Billion)
Figure 13.14 Site Management Organizations Market in France, 2021-2035 (USD Billion)
Figure 13.15 Site Management Organizations Market in Germany, 2021-2035 (USD Billion)
Figure 13.16 Site Management Organizations Market in Spain, 2021-2035 (USD Billion)
Figure 13.17 Site Management Organizations Market in Italy, 2021-2035 (USD Billion)
Figure 13.18 Site Management Organizations Market in Rest of Europe, 2021-2035 (USD Billion)
Figure 13.19 Site Management Organizations Market in Asia-Pacific, 2021-2035 (USD Billion)
Figure 13.20 Site Management Organizations Market in China, 2021-2035 (USD Billion)
Figure 13.21 Site Management Organizations Market in Korea, 2021-2035 (USD Billion)
Figure 13.22 Site Management Organizations Market in India, 2021-2035 (USD Billion)
Figure 13.23 Site Management Organizations Market in Australia, 2021-2035 (USD Billion)
Figure 13.24 Site Management Organizations Market in Japan, 2021-2035 (USD Billion)
Figure 13.25 Site Management Organizations Market in Israel, 2021-2035 (USD Billion)
Figure 13.26 Site Management Organizations Market in Rest of Asia-Pacific, 2021-2035 (USD Billion)
Figure 13.27 Site Management Organizations Market in Latin America, 2021-2035 (USD Billion)
Figure 13.28 Site Management Organizations Market in MENA, 2021-2035 (USD Billion)
Figure 13.29 Site Management Organizations Market in Rest of the World, 2021-2035 (USD Billion)
Figure 14.1 Concluding Remarks: Overall Market Landscape
Figure 14.2 Concluding Remarks: Partnerships and Collaborations
Figure 14.3 Concluding Remarks: Funding and Investment
Figure 14.4 Concluding Remarks: Clinical Trial Key Insights
Figure 14.5 Concluding Remarks: Analysis of Demand for Clinical Trial Participants
Figure 14.6 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Comparison of SMOs and CROs
Table 4.1 List of Site Management Organizations
Table 4.2 Site Management Organizations: Information on Type of Site Management Service(s) offered
Table 4.3 Site Management Organizations: Information on Therapeutic Expertise
Table 6.1 Site Management Organizations: List of Profiled Companies (North America)
Table 6.2 FOMAT Medical Research: Company Snapshot
Table 6.3 FOMAT Medical Research: Clinical Trial Site Management Service Portfolio
Table 6.4 FOMAT Medical Research: Recent Developments and Future Outlook
Table 6.5 Parexel: Company Snapshot
Table 6.6 Parexel: Clinical Trial Site Management Service Portfolio
Table 6.7 Paraxel: Recent Developments and Future Outlook
Table 6.8 Pharm-Olam: Company Snapshot
Table 6.9 Pharm-Olam: Clinical Trial Site Management Service Portfolio
Table 6.10 Pharm-Olam: Recent Developments and Future Outlook
Table 6.11 Veristat: Company Snapshot
Table 6.12 Veristat: Clinical Trial Site Management Service Portfolio
Table 6.13 Veristat: Recent Developments and Future Outlook
Table 6.14 WCCT Global: Company Snapshot
Table 6.15 WCCT Global: Clinical Trial Site Management Service Portfolio
Table 6.16 WCCT Global: Recent Developments and Future Outlook
Table 7.1 Site Management Organizations: List of Profiled Companies (Europe)
Table 7.2 CROMSOURCE: Company Snapshot
Table 7.3 CROMSOURCE: Clinical Trial Site Management Service Portfolio
Table 7.4 CROMSOURCE: Recent Developments and Future Outlook
Table 7.5 FIDELIS RESEARCH: Company Snapshot
Table 7.6 FIDELIS RESEARCH: Clinical Trial Site Management Service Portfolio
Table 7.7 FIDELIS RESEARCH: Recent Developments and Future Outlook
Table 7.8 Scandinavian CRO: Company Snapshot
Table 7.9 Scandinavian CRO: Clinical Trial Site Management Service Portfolio
Table 7.10 Scandinavian CRO: Recent Developments and Future Outlook
Table 7.11 TFS HealthScience: Company Snapshot
Table 7.12 TFS HealthScience: Clinical Trial Site Management Service Portfolio
Table 7.13 TFS HealthScience: Recent Developments and Future Outlook
Table 7.14 Trialbee: Company Snapshot
Table 7.15 Trialbee: Clinical Trial Site Management Service Portfolio
Table 7.16 Trialbee: Recent Developments and Future Outlook
Table 8.1 Site Management Organizations: List of Profiled Companies (Asia-Pacific)
Table 8.2 CMIC Group: Company Snapshot
Table 8.3 CMIC Group: Clinical Trial Site Management Service Portfolio
Table 8.4 CMIC Group: Recent Developments and Future Outlook
Table 8.5 George Clinical: Company Snapshot
Table 8.6 George Clinical: Clinical Trial Site Management Service Portfolio
Table 8.7 George Clinical: Recent Developments and Future Outlook
Table 8.8 Tigermed: Company Snapshot
Table 8.9 Tigermed: Clinical Trial Site Management Service Portfolio
Table 8.10 Tigermed: Recent Developments and Future Outlook
Table 8.11 Veeda Clinical Research: Company Snapshot
Table 8.12 Veeda Clinical Research: Clinical Trial Site Management Service Portfolio
Table 8.13 Veeda Clinical Research: Recent Developments and Future Outlook
Table 9.1 Site Management Organizations: List of Partnerships and Collaborations, 2016-2021
Table 10.1 Site Management Organizations: List of Funding and Investments, 2015-2021
Table 12.1 Global Demand for Clinical Trial Participants: Average Number of Patients Enrolled by Trial Phase
Table 16.1 Site Management Organizations: Distribution by Year of Establishment
Table 16.2 Site Management Organizations: Distribution by Company Size
Table 16.3 Site Management Organizations: Distribution by Location of Headquarters (Region-wise)
Table 16.4 Site Management Organizations: Distribution by Location of Headquarters (Country-wise)
Table 16.5 Site Management Organizations: Distribution by Company Size and Location of Headquarters
Table 16.6 Site Management Organizations: Distribution by Service(s) Offered
Table 16.7 Site Management Organizations: Distribution by Location of Headquarters and Service(s) Offered
Table 16.8 Site Management Organizations: Distribution by Therapeutic Expertise
Table 16.9 Site Management Organizations: Distribution by Geographical Reach
Table 16.10 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2021
Table 16.11 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.12 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 16.13 Partnerships and Collaborations: Distribution by Type of Partnership, 2016-2018 and 2019-2021
Table 16.14 Partnerships and Collaborations: Distribution by Focus Area
Table 16.15 Most Active Players: Distribution by Number of Partnerships
Table 16.16 Partnerships and Collaborations: Distribution by Region
Table 16.17 Partnerships and Collaborations: Distribution by Country
Table 16.18 Funding and Investment Analysis: Cumulative Year-wise Trend, 2015-2021
Table 16.19 Funding and Investment Analysis: Cumulative Year-wise Trend by Amount Invested, 2015-2021 (USD Million)
Table 16.20 Funding and Investment Analysis: Distribution by Type of Funding
Table 16.21 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 16.22 Funding and Investment Analysis: Year-wise Distribution by Amount Invested and Type of Funding, 2015-2021 (USD Million)
Table 16.23 Most Active Players: Distribution by Number of Funding Instances
Table 16.24 Most Active Investors: Distribution by Number of Funding Instances
Table 16.25 Funding and Investment Analysis: Distribution by Type of Investor
Table 16.26 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
Table 16.27 Funding and Investment Analysis: Distribution by Region (Continent-wise)
Table 16.28 Funding and Investment Analysis: Distribution by Region (Country-wise)
Table 10.29 Funding and Investment Analysis: Distribution of Amount Invested by Region (Country-wise) (USD Million)
Table 16.30 Clinical Trial Key Insights: Cumulative Distribution by Trial Registration Year, 2016-2021
Table 16.31 Clinical Trial Key Insights: Distribution by Trial Registration Year and Enrolled Patient Population, 2016-2021
Table 16.32 Clinical Trial Key Insights: Distribution by Trial Status
Table 16.33 Clinical Trial Key Insights: Distribution by Trial Registration Year and Trial Status, 2016-2021
Table 16.34 Clinical Trial Key Insights: Distribution of Number of Trials by Trial Phase
Table 16.35 Clinical Trial Key Insights: Distribution of Enrolled Patient Population by Trial Phase
Table 16.36 Clinical Trial Key Insights: Year-wise Distribution by Number of Trials and Trial Phase, 2016-2021
Table 16.37 Clinical Trial Key Insights: Year-wise Distribution by Number of Enrolled Patient Population and Trial Phase, 2016-2021
Table 16.38 Clinical Trial Key Insights: Distribution by Type of Sponsor / Collaborator
Table 16.39 Clinical Trial Key Insights: Geographical Distribution by Number of Clinical Trials
Table 16.40 Clinical Trial Key Insights: Geographical Distribution by Enrolled Patient Population
Table 16.41 Global Demand for Clinical Trial Participants, 2021-2035 (Million Patients)
Table 16.42 Global Demand for Clinical Trial Participants: Distribution by Therapeutic Area (Million Patients)
Table 16.43 Global Demand for Clinical Trial Participants: Distribution by Trial Phase (Million Patients)
Table 16.44 Global Demand for Clinical Trial Participants: Distribution by Region (Million Patients)
Table 16.45 Global Site Management Organizations Market, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.46 Site Management Organizations Market, 2021 and 2035: Distribution by Therapeutic Area (USD Billion)
Table 16.47 Site Management Organizations Market, 2021-2035: Distribution by Trial Phase (USD Billion)
Table 16.48 Site Management Organizations Market, 2021: Distribution by Clinical Trial Components (USD Billion)
Table 16.49 Site Management Organizations Market, 2021-2035: Distribution by Type of Intervention (USD Billion)
Table 16.50 Site Management Organizations Market, 2021 and 2035: Distribution by Region (USD Billion)
Table 16.51 Site Management Organizations Market, 2021 and 2035: Distribution by Country (USD Billion)
Table 16.52 Site Management Organizations Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.53 Site Management Organizations Market in the US, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.54 Site Management Organizations Market in Canada, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.55 Site Management Organizations Market in Rest of North America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.56 Site Management Organizations Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.57 Site Management Organizations Market in the UK, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.58 Site Management Organizations Market in France, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.59 Site Management Organizations Market in Germany, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.60 Site Management Organizations Market in Spain, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.61 Site Management Organizations Market in Italy, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.62 Site Management Organizations Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.63 Site Management Organizations Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.64 Site Management Organizations Market in China, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.65 Site Management Organizations Market in Korea, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.66 Site Management Organizations Market in India, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.67 Site Management Organizations Market in Australia, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.68 Site Management Organizations Market in Japan, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.69 Site Management Organizations Market in Israel, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.70 Site Management Organizations Market in Rest of Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.71 Site Management Organizations Market in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.72 Site Management Organizations Market in MENA, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)
Table 16.73 Site Management Organizations Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 23andMe
  2. 3H Medi Solution
  3. 3S Pharma
  4. Accel Clinical Services
  5. Accell Clinical Research
  6. Accelovance 
  7. accerise
  8. Access Clinical Research
  9. Ace Research
  10. ACI Clinical
  11. Acrostar SMO
  12. ACTG-CRO
  13. Advanced Clinical
  14. Aetion 
  15. Affiliated Clinical Research
  16. AiCure
  17. Alpha Oncology Research (AOR)
  18. Altasciences
  19. Amadeus Capital Partners
  20. AmberCRO
  21. American Liver Foundation
  22. American Research Associates (ARA)
  23. AmerisourceBergen 
  24. Analgesic Solutions
  25. Andronovo Labs 
  26. Anteris Bio
  27. Antev 
  28. Antidote
  29. AOBiome Therapeutics
  30. Apex Medical Research
  31. APF Research
  32. ApotheCom
  33. Apptomics
  34. Aptitude Health
  35. Ardent Clinical Research Services
  36. Asian Eye Institute
  37. Associated Medical 
  38. Association of Clinical Research Professionals (ACRP)
  39. AstraZeneca 
  40. Atlant Clinical
  41. Aurum Clinical Research
  42. AusTrials
  43. AutoCruitment
  44. Avacare 
  45. AXELLE Group
  46. AXIM Biotechnologies
  47. BBK Worldwide
  48. Beijing Aisimo Medical Science and Technology
  49. Beijing CTSMED
  50. Beijing EasyTrial MedTech 
  51. Beijing Global Pharmaceutical Research (Acquired by EPS International)
  52. Beijing Illness Challenge Foundation (ICF)
  53. Best Clinical Practice
  54. Bioclinica
  55. Biomapas
  56. Biomedical Advanced Research and Development Authority (BARDA)
  57. Biomic Lifescience
  58. Biosite Research
  59. Box
  60. BrainStorm Cell Therapeutics
  61. Briban Invest
  62. Bridge Clinical Research
  63. BTC Network
  64. Cactus Clinical Research
  65. Calmark 
  66. Canadian Centre for Clinical Trials (CCCT)
  67. Cardialysis
  68. CaringKind
  69. Caris Life Sciences
  70. Carpathian Research
  71. Catalyst Regulatory Services (Acquired by Veristat)
  72. CCT Research
  73. Central India Clinical Research Services (CICRS) 
  74. Centre International de Développement Pharmaceutique (CIDP)
  75. Chase Medical Research
  76. ChiG 
  77. Chrondel 
  78. Cidara Therapeutics
  79. Cinven
  80. Clariness 
  81. Cliantha Research
  82. Clin Sol 
  83. Clinade Clinical Research
  84. Clinart MENA
  85. ClinChoice
  86. ClinEdge 
  87. Clinerion
  88. Clinexa Life Sciences
  89. Clinical Accelerator
  90. Clinical Development Solutions (CDS)
  91. Clinical Endpoints 
  92. Clinical Investigation Centre (University Malaya Medical Centre)
  93. Clinical Research Fastrack
  94. Clinical Research Partners
  95. Clinical Trial Networking (CT-N)
  96. Clinical Trials Management Solutions (CTMS)
  97. ClinicalConnection
  98. Clinipace
  99. CLINISYD 
  100. Clinixir
  101. ClinROtech
  102. ClinSmart
  103. Clinsol
  104. Clinspire Research
  105. Clintec
  106. Clintract 
  107. ClinVax 
  108. Clinverse
  109. ClinWin Research Services 
  110. CLS-Ukraine
  111. CluePoints
  112. CMIC Group
  113. CMX Research
  114. CNS Pharmaceuticals
  115. COD Research
  116. Comac Medical
  117. COMPASS Pathways
  118. Compass Research
  119. Continuum Clinical
  120. Cosmic Clinical Services
  121. Credevo 
  122. Crestline Investors
  123. CRO Pharmatrendz
  124. Croissance Clinical Research
  125. CROMSOURCE 
  126. CRS Clinical Research Services
  127. CTC North
  128. CTI Clinical Trial and Consulting Services 
  129. CTM
  130. CX Partners
  131. Cyclo Therapeutics
  132. Cytespace 
  133. DAC Patient Recruitment Services
  134. Datavant
  135. DAVA Oncology
  136. DaVita Clinical Research
  137. Deep Lens
  138. Deerfield Management
  139. DEMEDICA
  140. Devana Solutions
  141. DFnet
  142. Dimension Research
  143. Direct Biologics
  144. dMed
  145. Duke Clinical Research Institute (DCRI) 
  146. eClinical Solutions
  147. Edenwell Therapeutics
  148. EDETEK
  149. Effectus CTR
  150. EGeen
  151. Elligo Health Research
  152. EMMES
  153. emovis 
  154. Empower Capital
  155. EPS Associates
  156. EPS International
  157. EQT
  158. ERT
  159. ESTERN Medical 
  160. Estudios Clínicos Latinoamérica (ECLA)
  161. Ethicscare Clinical Research Services (ECRS)
  162. EthosExcel
  163. Everest Clinical Research
  164. Evolution Research Group (ERG)
  165. Experior 
  166. F2 Ventures
  167. FARMEPO
  168. FDAMap
  169. Febo
  170. FedDev Ontario
  171. FHI Clinical
  172. Fidelis Research
  173. FOMAT Medical Research
  174. Foundation Medicine
  175. Free to Breathe
  176. Frenova Renal Research
  177. Fresenius Medical Care
  178. Gaea
  179. Gama CRO
  180. GB Sciences 
  181. GCP Clinical Studies
  182. GCP Research
  183. G CURE Healthcare
  184. GDD Experts
  185. Genentech
  186. General Atlantic
  187. George Clinical
  188. GIC
  189. Global Clinical Trials
  190. Goldman Sachs Asset Management International (GSAMI)
  191. Gratisol Labs
  192. GSK
  193. GuideStar Research
  194. Haihe Biopharma 
  195. Hatteras Venture Partners
  196. Haxon Life Sciences
  197. Healing Hands Clinical Research Services (HHCRS)
  198. HealthVerity
  199. Horizon Research
  200. Hospital Alemão Oswaldo Cruz 
  201. EI Hospital de Especialidades Teodoro Maldonado Carbo
  202. Hoth Therapeutics 
  203. hyperCORE International
  204. I’rom Group
  205. iCo Therapeutics
  206. iDD Research Solutions
  207. IKCON PHARMA
  208. Illingworth Research Group
  209. InClin
  210. Incred CR
  211. Indian Institute of Clinical Research & Management (IICRM)
  212. Industrifonden
  213. Infectious Disease Research Institute (IDRI)
  214. InformedDNA
  215. Innoplexus 
  216. Innovaderm
  217. Innovate Research
  218. Insignia Clinical Services (ICS)
  219. INSPIRE
  220. Integrity Capital Wealth Management
  221. Inteliquet
  222. International Research Networks (IRN)
  223. Intouch Clinical Research Center 
  224. Intrinsic Imaging (Acquired by WCG)
  225. Invicro 
  226. IPHARMA 
  227. IQVIA
  228. ITOCHU
  229. ITOCHU Technology Ventures
  230. Johnson Clinical Research
  231. Juno Research
  232. Karyopharm Therapeutics
  233. Klinar CRO
  234. KlinEra 
  235. KMR Group
  236. Komplett Clinical Research (KCR)
  237. KPS Clinical Services
  238. KV Clinical Research Services (KVCR)
  239. Kyung Hee University Hospital 
  240. LEADS Clinical Research and Bio Services
  241. Limbix
  242. Linical Americas
  243. Link Health
  244. LITMUS 
  245. LiveRamp
  246. LMC Manna Research
  247. Lyft
  248. MakroCare
  249. Marshfield Clinic Research Institute
  250. Mary Bird Perkins Cancer Center
  251. Mayo Clinic
  252. med fusion (Acquired by Quest Diagnostics)
  253. Medable
  254. MedAvante-ProPhase (Acquired by WCG)
  255. MEDEX 
  256. Median Technologies
  257. Medicor Research
  258. Medicus Alliance
  259. Medicus Health Partners
  260. Medidata 
  261. Melanoma Research Alliance
  262. MENE Health Group
  263. Merck
  264. Merck Global Health Innovation Fund (GHI)
  265. Metrics Champion Consortium (MCC) (Acquired by WCG)
  266. Mitsui
  267. MMG
  268. Molecular Templates
  269. Montserrat Day Hospitals
  270. MPM Capital
  271. MPR Development Group
  272. MTIP
  273. Muscular Dystrophy Association (MDA)
  274. National Cancer Center
  275. National Institute of Clinical Research (NICR)
  276. National Taiwan University Hospital (NTUH)
  277. NeoGenomics
  278. Newton Clinical Research
  279. NextPhase Research
  280. Nomad Life Sciences 
  281. North Estonia Medical Centre
  282. Novotech
  283. nRollmed
  284. Nucleon Therapeutics
  285. O4 Research
  286. Oaxaca Site Management Organization (OSMO)
  287. Octopus Investments
  288. Octopus Ventures
  289. Okogen
  290. OneOncology
  291. Optimum CRO
  292. Ora
  293. Oracle
  294. orphan reach
  295. Orphanos
  296. Ospedale San Raffaele
  297. P3 Research
  298. Panthera
  299. Parallel 6 (Acquired by PRA Health Sciences)
  300. Parexel 
  301. PAS Research
  302. PatientPoint 
  303. Peachtree BioResearch Solutions
  304. Penta ID Innovation
  305. Pepgra
  306. Pfizer
  307. Pharmatech
  308. Pharm-Olam 
  309. phaware 
  310. Physicians Research Group (PRG)
  311. Plexus Research
  312. Polaris Biopharma Consulting
  313. PPC Group
  314. PPD
  315. Prabhans Clinical Services
  316. Praxis
  317. Precision for Medicine
  318. Precision Health
  319. Prime Site
  320. Prodia 
  321. Protocol First
  322. ProTrials Research
  323. Prudentia 
  324. Psilera 
  325. Puerto Rico Consortium for Clinical Investigation (PRCCI)
  326. Pulse Clinical Research
  327. Pusan National University Hospital (PNUH)
  328. PWNHealth
  329. QAscent Research Solutions
  330. QPS
  331. Quad-C Management
  332. Quanticate 
  333. Quantime World 
  334. Quest Diagnostics 
  335. Quintessential Solutions
  336. Ravek 
  337. RealTime Software Solutions
  338. Red Maple Trials
  339. RemediumOne 
  340. Research Trials Group
  341. RESolutions
  342. Reumalab
  343. Revive Therapeutics
  344. Richmond Behavioral Associates (RBA)
  345. Rock Springs Capital
  346. Rutherford Health plc
  347. S4 Research
  348. Sabre Partners
  349. Samahitha Research Solutions
  350. Sandia Clinical Research
  351. Sanjeevani 
  352. Sanofi 
  353. Santa Maria Gastroenterology
  354. Scandinavian CRO 
  355. S-Clinical
  356. SDS Clinical
  357. Sequoia Capital
  358. SGS Life Science Services
  359. Shanghai Shoujia Medical Clinical Research
  360. SiChaGi Medical Solutions
  361. SIGAL SMS
  362. Signify Health
  363. SitePartner
  364. Skin Research Institute of Singapore (SRIS)
  365. Skylight Health
  366. Smedvig Capital
  367. SMO – DRA. MARISA VICO 
  368. SMO Clinical Research (SMO-India)
  369. SMO ClinPlus
  370. SMO UCT
  371. SMOconnect 
  372. Smooth Drug Development
  373. SMO-Pharmina 
  374. Society for Clinical Research Sites
  375. Solutions OP
  376. Somaya Research and Health Services
  377. SoMex Research & Health Organisation
  378. Sonic Clinical Trials
  379. Spectral Medical
  380. Spectrum Clinical Research
  381. Spero Oncology (Acquired by Veristat)
  382. SPRI Ukraine
  383. Springhill Fund
  384. SQN Clinical
  385. Statistics Collaborative
  386. Superstring Capital
  387. Surescripts
  388. Syncretic Clinical Research Services
  389. Syneos Health
  390. Syntax 
  391. Synteract
  392. Syreon 
  393. Takeda Pharmaceutical
  394. Terveystalo
  395. TFS HealthScience
  396. Association of Clinical Research Professionals (ACRP)
  397. The Buffalo-Niagara Clinical Alliance (BNCA)
  398. The Clinical Trial Company (TCTC) (Acquired by Veristat)
  399. The Clinic'les
  400. THREAD
  401. ThreeWire
  402. Tigermed
  403. Tiziana Life Sciences
  404. Topstone Research
  405. Total Clinical Trial Management
  406. Translational Research in Oncology (TRIO)
  407. Trial Management Group (TMG)
  408. Trialbee
  409. TrialSpark
  410. Trifecta (acquired by WCG)
  411. TriNetX
  412. Triumph Research Intelligence (TRI)
  413. Triumpharma 
  414. United States Department of Defense (DOD)
  415. uMotif
  416. Unicorn Protego Site Management Organization (UP SMO)
  417. United BioSource (UBC)
  418. University of Yamanshi 
  419. Urgent Care Clinical Trials
  420. Vector Oncology
  421. Veeda Clinical Research
  422. Veeva Systems
  423. VeraSci
  424. Veristat 
  425. Vicore Pharma
  426. Vigilare International
  427. Viomedo
  428. Virgo
  429. Walter and Eliza Hall Institute of Medical Research (WEHI)
  430. WCCT Global
  431. WCG
  432. WCG Avoca
  433. WCG PharmaSeek
  434. WindRose Health Investors
  435. Worldwide Clinical Trials
  436. WuXi Clinical (a WuXi AppTec Company)
  437. Xcene Research
  438. Xylem Clinical Research 
  439. Zagvo Portal
  440. Zarta Life
  441. Zosano Pharma

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com